Compare ALEMBIC PHARMA with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs STERLING BIOTECH - Comparison Results

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA STERLING BIOTECH ALEMBIC PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 15.8 -0.4 - View Chart
P/BV x 3.6 0.0 25,450.3% View Chart
Dividend Yield % 1.1 0.0 -  

Financials

 ALEMBIC PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
STERLING BIOTECH
Dec-13
ALEMBIC PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs66411 6,323.8%   
Low Rs4123 12,129.4%   
Sales per share (Unadj.) Rs208.726.8 778.6%  
Earnings per share (Unadj.) Rs31.0-15.0 -207.2%  
Cash flow per share (Unadj.) Rs37.1-5.5 -679.3%  
Dividends per share (Unadj.) Rs5.500-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs144.254.9 262.8%  
Shares outstanding (eoy) m188.52267.87 70.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.60.3 994.6%   
Avg P/E ratio x17.4-0.5 -3,736.5%  
P/CF ratio (eoy) x14.5-1.3 -1,139.9%  
Price / Book Value ratio x3.70.1 2,946.9%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m101,4611,862 5,449.9%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m7,467547 1,365.6%   
Avg. sales/employee Rs ThNM5,303.3-  
Avg. wages/employee Rs ThNM403.8-  
Avg. net profit/employee Rs ThNM-2,959.0-  
INCOME DATA
Net Sales Rs m39,3477,181 548.0%  
Other income Rs m9443 220.2%   
Total revenues Rs m39,4417,223 546.0%   
Gross profit Rs m8,736947 922.6%  
Depreciation Rs m1,1522,543 45.3%   
Interest Rs m1844,377 4.2%   
Profit before tax Rs m7,493-5,931 -126.3%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,568-1,924 -81.5%   
Profit after tax Rs m5,844-4,007 -145.9%  
Gross profit margin %22.213.2 168.4%  
Effective tax rate %20.932.4 64.5%   
Net profit margin %14.9-55.8 -26.6%  
BALANCE SHEET DATA
Current assets Rs m19,57714,335 136.6%   
Current liabilities Rs m14,89649,809 29.9%   
Net working cap to sales %11.9-494.0 -2.4%  
Current ratio x1.30.3 456.7%  
Inventory Days Days90403 22.2%  
Debtors Days Days45171 26.6%  
Net fixed assets Rs m27,09755,432 48.9%   
Share capital Rs m377268 140.7%   
"Free" reserves Rs m26,81113,935 192.4%   
Net worth Rs m27,18814,701 184.9%   
Long term debt Rs m4,9939,478 52.7%   
Total assets Rs m47,77873,988 64.6%  
Interest coverage x41.7-0.4 -11,748.3%   
Debt to equity ratio x0.20.6 28.5%  
Sales to assets ratio x0.80.1 848.6%   
Return on assets %12.60.5 2,518.8%  
Return on equity %21.5-27.3 -78.9%  
Return on capital %23.6-6.4 -367.3%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m19,4531,860 1,046.0%   
Fx outflow Rs m6,06525 24,366.4%   
Net fx Rs m13,3881,835 729.6%   
CASH FLOW
From Operations Rs m8,1201,719 472.4%  
From Investments Rs m-7,556-3,148 240.0%  
From Financial Activity Rs m5901,426 41.4%  
Net Cashflow Rs m1,153-3 -33,920.6%  

Share Holding

Indian Promoters % 74.1 33.9 218.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 0.0 -  
FIIs % 9.1 9.9 91.9%  
ADR/GDR % 0.0 16.9 -  
Free float % 13.9 39.3 35.4%  
Shareholders   49,328 21,482 229.6%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Bajaj Finance and ICICI Bank Top Gainers(12:30 pm)

Stock markets in India are presently trading on a positive note. The BSE Sensex is trading up by 90 points and the NSE Nifty is trading up by 35 points.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Oct 16, 2019 02:51 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS